Checkpoint Therapeutics’ (CKPT) Buy Rating Reiterated at HC Wainwright

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $20.00 price target on the stock.

Checkpoint Therapeutics Trading Up 3.0 %

CKPT stock traded up $0.07 during mid-day trading on Monday, hitting $2.37. 264,999 shares of the company were exchanged, compared to its average volume of 446,938. Checkpoint Therapeutics has a 1-year low of $1.30 and a 1-year high of $3.62. The stock has a market capitalization of $106.70 million, a PE ratio of -0.85 and a beta of 1.29. The business has a 50 day simple moving average of $2.32 and a 200-day simple moving average of $2.02.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.11. The firm had revenue of $0.04 million for the quarter. Equities research analysts expect that Checkpoint Therapeutics will post -0.81 earnings per share for the current year.

Insider Activity

In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 24,610 shares of Checkpoint Therapeutics stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $2.05, for a total value of $50,450.50. Following the completion of the sale, the chief executive officer now owns 1,977,170 shares in the company, valued at approximately $4,053,198.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 24,610 shares of the stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $2.05, for a total transaction of $50,450.50. Following the sale, the chief executive officer now directly owns 1,977,170 shares in the company, valued at $4,053,198.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO William Garrett Gray sold 13,038 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total transaction of $26,858.28. Following the completion of the transaction, the chief financial officer now directly owns 672,186 shares in the company, valued at $1,384,703.16. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Checkpoint Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in shares of Checkpoint Therapeutics in the 2nd quarter valued at $34,000. Lindbrook Capital LLC acquired a new stake in shares of Checkpoint Therapeutics in the 1st quarter valued at approximately $62,000. 180 Wealth Advisors LLC acquired a new stake in shares of Checkpoint Therapeutics in the 2nd quarter valued at approximately $96,000. Choreo LLC grew its holdings in shares of Checkpoint Therapeutics by 200.9% during the 1st quarter. Choreo LLC now owns 57,922 shares of the company’s stock valued at $119,000 after purchasing an additional 38,672 shares during the last quarter. Finally, PVG Asset Management Corp acquired a new position in Checkpoint Therapeutics during the 2nd quarter worth approximately $295,000. 22.00% of the stock is currently owned by institutional investors.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.